IT1306704B1 - Anticorpi monoclonali e suoi derivati sintetici o biotecnologici ingrado di agire come molecole antagoniste per il ngf. - Google Patents

Anticorpi monoclonali e suoi derivati sintetici o biotecnologici ingrado di agire come molecole antagoniste per il ngf.

Info

Publication number
IT1306704B1
IT1306704B1 IT1999RM000333A ITRM990333A IT1306704B1 IT 1306704 B1 IT1306704 B1 IT 1306704B1 IT 1999RM000333 A IT1999RM000333 A IT 1999RM000333A IT RM990333 A ITRM990333 A IT RM990333A IT 1306704 B1 IT1306704 B1 IT 1306704B1
Authority
IT
Italy
Prior art keywords
ngf
act
synthetic
monoclonal antibodies
antagonist molecules
Prior art date
Application number
IT1999RM000333A
Other languages
English (en)
Inventor
Michal Novak
Original Assignee
Sirs Societa Italiana Per La R
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=11406787&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IT1306704(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Sirs Societa Italiana Per La R filed Critical Sirs Societa Italiana Per La R
Priority to IT1999RM000333A priority Critical patent/IT1306704B1/it
Publication of ITRM990333A0 publication Critical patent/ITRM990333A0/it
Priority to AT00935482T priority patent/ATE263188T1/de
Priority to PCT/IT2000/000218 priority patent/WO2000073344A2/en
Priority to PT00935482T priority patent/PT1181318E/pt
Priority to EP00935482A priority patent/EP1181318B2/en
Priority to JP2001500668A priority patent/JP4917226B2/ja
Priority to ES00935482T priority patent/ES2218163T5/es
Priority to DK00935482.0T priority patent/DK1181318T4/da
Priority to AU51019/00A priority patent/AU776457B2/en
Priority to DE60009484T priority patent/DE60009484T3/de
Priority to CA2373274A priority patent/CA2373274C/en
Priority to US09/979,710 priority patent/US7601352B1/en
Publication of ITRM990333A1 publication Critical patent/ITRM990333A1/it
Publication of IT1306704B1 publication Critical patent/IT1306704B1/it
Application granted granted Critical
Priority to US12/557,825 priority patent/US8486401B2/en
Priority to JP2011180419A priority patent/JP2012040007A/ja

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
IT1999RM000333A 1999-05-26 1999-05-26 Anticorpi monoclonali e suoi derivati sintetici o biotecnologici ingrado di agire come molecole antagoniste per il ngf. IT1306704B1 (it)

Priority Applications (14)

Application Number Priority Date Filing Date Title
IT1999RM000333A IT1306704B1 (it) 1999-05-26 1999-05-26 Anticorpi monoclonali e suoi derivati sintetici o biotecnologici ingrado di agire come molecole antagoniste per il ngf.
US09/979,710 US7601352B1 (en) 1999-05-26 2000-05-26 Monoclonal antibodies and antigen binding fragments thereof capable of binding TrkA and inhibiting the functional activation of TrkA
DK00935482.0T DK1181318T4 (da) 1999-05-26 2000-05-26 Monoklonale antistoffer samt syntetiske og bioteknologiske derivater deraf, der virker som NGF-antagonistmolekyler
AU51019/00A AU776457B2 (en) 1999-05-26 2000-05-26 Monoclonal antibodies, synthetic and biotechnological derivatives thereof acting as NGF-antagonist molecules
PT00935482T PT1181318E (pt) 1999-05-26 2000-05-26 Anticorpos monoclonais seus derivados sinteticos e biotecnologicos actuando como moleculas antagonistas de nge
EP00935482A EP1181318B2 (en) 1999-05-26 2000-05-26 Monoclonal antibodies, synthetic and biotechnological derivatives thereof acting as ngf-antagonist molecules
JP2001500668A JP4917226B2 (ja) 1999-05-26 2000-05-26 Ｎｇｆ−アンタゴニスト分子として作用するモノクローナル抗体、その合成及び生命工学的誘導体
ES00935482T ES2218163T5 (es) 1999-05-26 2000-05-26 Anticuerpos monoclonales y sus derivados sintéticos y biotecnológicos que actúan como moléculas antagonistas de NGF
AT00935482T ATE263188T1 (de) 1999-05-26 2000-05-26 Als ngf-antagonisten wirkende monoklonale antiköper und deren synthetische und biotechnologische derivate
PCT/IT2000/000218 WO2000073344A2 (en) 1999-05-26 2000-05-26 Monoclonal antibodies, synthetic and biotechnological derivatives thereof acting as ngf-antagonist molecules
DE60009484T DE60009484T3 (de) 1999-05-26 2000-05-26 Als ngf-antagonisten wirkende monoklonale antiköper und deren synthetische und biotechnologische derivate
CA2373274A CA2373274C (en) 1999-05-26 2000-05-26 Monoclonal antibodies, synthetic and biotechnological derivatives thereof acting as ngf-antagonist molecules
US12/557,825 US8486401B2 (en) 1999-05-26 2009-09-11 Monoclonal antibodies binding to TrkA and acting as NGF-antagonist molecules and their use for treating pain induced by NGF
JP2011180419A JP2012040007A (ja) 1999-05-26 2011-08-22 Ｎｇｆ−アンタゴニスト分子として作用するモノクローナル抗体、その合成及び生命工学的誘導体

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IT1999RM000333A IT1306704B1 (it) 1999-05-26 1999-05-26 Anticorpi monoclonali e suoi derivati sintetici o biotecnologici ingrado di agire come molecole antagoniste per il ngf.

Publications (3)

Publication Number Publication Date
ITRM990333A0 ITRM990333A0 (it) 1999-05-26
ITRM990333A1 ITRM990333A1 (it) 2000-11-26
IT1306704B1 true IT1306704B1 (it) 2001-10-02

Family

ID=11406787

Family Applications (1)

Application Number Title Priority Date Filing Date
IT1999RM000333A IT1306704B1 (it) 1999-05-26 1999-05-26 Anticorpi monoclonali e suoi derivati sintetici o biotecnologici ingrado di agire come molecole antagoniste per il ngf.

Country Status (12)

Country Link
US (2) US7601352B1 (it)
EP (1) EP1181318B2 (it)
JP (2) JP4917226B2 (it)
AT (1) ATE263188T1 (it)
AU (1) AU776457B2 (it)
CA (1) CA2373274C (it)
DE (1) DE60009484T3 (it)
DK (1) DK1181318T4 (it)
ES (1) ES2218163T5 (it)
IT (1) IT1306704B1 (it)
PT (1) PT1181318E (it)
WO (1) WO2000073344A2 (it)

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1306704B1 (it) * 1999-05-26 2001-10-02 Sirs Societa Italiana Per La R Anticorpi monoclonali e suoi derivati sintetici o biotecnologici ingrado di agire come molecole antagoniste per il ngf.
FR2807660A1 (fr) * 2000-04-13 2001-10-19 Warner Lambert Co Utilisation d'antagonistes du ngf pour la prevention ou le traitement de douleurs viscerales chroniques
CA2448956C (en) * 2001-05-30 2017-10-03 Genentech, Inc. Anti-ngf antibodies for the treatment of various disorders
JP2006500004A (ja) * 2001-12-31 2006-01-05 スージェン・インコーポレーテッド 遠縁ホモログを検出する方法および該方法により同定される新規キナーゼ
UA80447C2 (en) 2002-10-08 2007-09-25 Methods for treating pain by administering nerve growth factor antagonist and opioid analgesic
DE60335957D1 (de) 2002-10-08 2011-03-17 Rinat Neuroscience Corp Verfahren zur behandlung von postoperativen schmerzen durch verabreichung eines antikörpers gegen nervenwachstumsfaktor und diesen enthaltende zusammensetzungen
DK1575517T3 (da) 2002-12-24 2012-05-14 Rinat Neuroscience Corp Anti-ngf-antistoffer og fremgangsmåder til anvendelse af samme
US7569364B2 (en) 2002-12-24 2009-08-04 Pfizer Inc. Anti-NGF antibodies and methods using same
US9498530B2 (en) 2002-12-24 2016-11-22 Rinat Neuroscience Corp. Methods for treating osteoarthritis pain by administering a nerve growth factor antagonist and compositions containing the same
CA2516454A1 (en) 2003-02-19 2004-09-02 Rinat Neuroscience Corp. Methods for treating pain by administering a nerve growth factor antagonist and an nsaid and compositions containing the same
ITRM20030601A1 (it) 2003-12-24 2005-06-25 Lay Line Genomics Spa Metodo per l'umanizzazione di anticorpi e anticorpi umanizzati con esso ottenuti.
TWI367101B (en) 2004-04-07 2012-07-01 Rinat Neuroscience Corp Methods for treating bone cancer pain by administering a nerve growth factor antagonist
AU2006207338B2 (en) 2005-01-24 2011-12-08 Elan Pharma International Limited Specific binding members for NGF
NZ561525A (en) 2005-02-16 2010-11-26 Astrazeneca Ab Benzimidazole compounds and analogues, containing a pyrazole ring, for inhibition of Trk activity, affecting cancer
WO2006123113A2 (en) 2005-05-16 2006-11-23 Astrazeneca Ab Pyrazolylaminopyrimidine derivatives useful as tyrosine kinase inhibitors
ITRM20050290A1 (it) * 2005-06-07 2006-12-08 Lay Line Genomics Spa Uso di molecole in grado di inibire il legame tra ngf e il suo recettore trka come analgesici ad effetto prolungato.
ITRM20050332A1 (it) 2005-06-24 2006-12-25 Lay Line Genomics Spa Uso di molecole in grado di bloccare l'attivita' di trka per potenziare gli effetti di analgesici oppiacei sul dolore.
DK1945631T3 (da) 2005-10-28 2012-10-22 Astrazeneca Ab 4- (3-aminopyrazole) pyrimidinderivater til anvendelse som tyrosinkinaseinhibitorer til behandling af cancer
TW200826937A (en) * 2006-11-01 2008-07-01 Astrazeneca Ab New use
UA99459C2 (en) 2007-05-04 2012-08-27 Астразенека Аб 9-(pyrazol-3-yl)- 9h-purine-2-amine and 3-(pyraz0l-3-yl)-3h-imidazo[4,5-b]pyridin-5-amine derivatives and their use for the treatment of cancer
US8309088B2 (en) 2007-08-10 2012-11-13 Regeneron Pharmaceuticals, Inc. Method of treating osteoarthritis with an antibody to NGF
ME02239B (me) 2007-08-10 2015-04-30 Regeneron Pharma Humana antitela visokog afiniteta prema humanom nervnom faktoru rasta
NZ587701A (en) 2008-02-04 2013-03-28 Lay Line Genomics Spa Anti-trka antibodies and derivatives thereof
KR101805754B1 (ko) 2008-12-08 2017-12-07 먼디파머 인터내셔널 코포레이션 리미티드 단백질 수용체 티로신 키나아제 억제제의 조성물
SI2448970T1 (sl) 2009-05-04 2014-11-28 Abbvie Research B.V. Protitelesa proti živčnemu rastnemu faktorju (NGF) s povečano stabilnostjo in vivo
PL3333188T3 (pl) 2010-08-19 2022-05-09 Zoetis Belgium S.A. Przeciwciała anty-ngf i ich zastosowanie
US9067988B2 (en) 2010-12-01 2015-06-30 Alderbio Holdings Llc Methods of preventing or treating pain using anti-NGF antibodies
US11214610B2 (en) 2010-12-01 2022-01-04 H. Lundbeck A/S High-purity production of multi-subunit proteins such as antibodies in transformed microbes such as Pichia pastoris
US9783601B2 (en) 2010-12-01 2017-10-10 Alderbio Holdings Llc Methods of preventing inflammation and treating pain using anti-NGF compositions
US9539324B2 (en) 2010-12-01 2017-01-10 Alderbio Holdings, Llc Methods of preventing inflammation and treating pain using anti-NGF compositions
US9884909B2 (en) 2010-12-01 2018-02-06 Alderbio Holdings Llc Anti-NGF compositions and use thereof
US9078878B2 (en) 2010-12-01 2015-07-14 Alderbio Holdings Llc Anti-NGF antibodies that selectively inhibit the association of NGF with TrkA, without affecting the association of NGF with p75
WO2013009582A1 (en) 2011-07-12 2013-01-17 Merck Sharp & Dohme Corp. TrkA KINASE INHIBITORS, COMPOSITIONS AND METHODS THEREOF
WO2013176970A1 (en) 2012-05-22 2013-11-28 Merck Sharp & Dohme Corp. TrkA KINASE INHIBITORS, COMPOSITIONS AND METHODS THEREOF
US9617334B2 (en) 2012-06-06 2017-04-11 Zoetis Services Llc Caninized anti-NGF antibodies and methods thereof
EP2859019B1 (en) 2012-06-08 2018-02-21 Glenmark Pharmaceuticals S.A. Humanized anti-trka antibodies with amino acid substitutions
EP2674439B1 (en) 2012-06-13 2017-02-01 Rottapharm Biotech S.r.l. Anti-TrkA antibodies, derivatives and uses thereof
WO2015039334A1 (en) 2013-09-22 2015-03-26 Merck Sharp & Dohme Corp. TrkA KINASE INHIBITORS, COMPOSITIONS AND METHODS THEREOF
WO2015039333A1 (en) 2013-09-22 2015-03-26 Merck Sharp & Dohme Corp. TrkA KINASE INHIBITORS, COMPOSITIONS AND METHODS THEREOF
NZ721057A (en) 2014-02-05 2023-04-28 VM Oncology LLC Compositions of compounds and uses thereof
WO2015143652A1 (en) 2014-03-26 2015-10-01 Merck Sharp & Dohme Corp. TrkA KINASE INHIBITORS,COMPOSITIONS AND METHODS THEREOF
WO2015143653A1 (en) 2014-03-26 2015-10-01 Merck Sharp & Dohme Corp. TrkA KINASE INHIBITORS,COMPOSITIONS AND METHODS THEREOF
WO2015143654A1 (en) 2014-03-26 2015-10-01 Merck Sharp & Dohme Corp. TrkA KINASE INHIBITORS,COMPOSITIONS AND METHODS THEREOF
MA41097A (fr) * 2014-12-05 2017-10-10 Glenmark Pharmaceuticals Sa Anticorps anti-trka à propriétés inhibitrices améliorées et dérivés desdits anticorps destinés à être utilisés pour traiter les douleurs osseuses
WO2016161572A1 (en) 2015-04-08 2016-10-13 Merck Sharp & Dohme Corp. TrkA KINASE INHIBITORS, COMPOSITIONS AND METHODS THEREOF
AR114110A1 (es) 2018-02-28 2020-07-22 Lilly Co Eli Anticuerpo anti-trka
BR112020017701A2 (pt) 2018-03-12 2020-12-29 Zoetis Services Llc Anticorpos anti-ngf e métodos dos mesmos
TW202210467A (zh) 2020-05-28 2022-03-16 美商美國禮來大藥廠 TrkA抑制劑
WO2023125490A1 (en) * 2021-12-28 2023-07-06 4B Technologies (Suzhou) Limited TrkA ANTIBODY AND APPLICATION THEREOF
US20230348608A1 (en) 2022-04-27 2023-11-02 Regeneron Pharmaceuticals, Inc. Treatment Of Arthropathy Based Upon Stratification Of Osteoarthritis Polygenic Risk Score

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1989009225A1 (en) * 1988-03-28 1989-10-05 The Regents Of The University Of California Nerve growth factor peptides
IL162181A (en) * 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
EP0471205A1 (en) 1990-08-15 1992-02-19 E.R. SQUIBB & SONS, INC. Monoclonal antibodies which bind TRK proto-oncogene protein
DE69233204T2 (de) * 1991-12-13 2004-07-15 Xoma Corp., Berkeley Verfahren und materialien zur herstellung von modifizierten variablen antikörperdomänen und ihre therapeutische verwendung
DE69333524T2 (de) * 1992-09-07 2005-06-16 Kyowa Hakko Kogyo Co., Ltd. Humanisierte Antikörper, die mit dem GM2-Gangliosid reagieren
SK285035B6 (sk) * 1992-10-28 2006-05-04 Genentech, Inc. Antagonisty rastového faktora vaskulárnych endotelových buniek
US5753225A (en) 1993-12-03 1998-05-19 The Regents Of The University Of California Antibodies that mimic actions of neurotrophins
US6811779B2 (en) * 1994-02-10 2004-11-02 Imclone Systems Incorporated Methods for reducing tumor growth with VEGF receptor antibody combined with radiation and chemotherapy
ATE283926T1 (de) * 1995-09-11 2004-12-15 Kyowa Hakko Kogyo Kk Antikörper gegen die alpha-kette von humanem interleukin 5 rezeptor
GB9525180D0 (en) 1995-12-08 1996-02-07 Univ Mcgill Design of hormone-like antibodies with agonistic and antagonistic fuctions
US20020064528A1 (en) * 2000-01-28 2002-05-30 Zhenping Zhu Antibodies specific to KDR and uses thereof
IT1306704B1 (it) * 1999-05-26 2001-10-02 Sirs Societa Italiana Per La R Anticorpi monoclonali e suoi derivati sintetici o biotecnologici ingrado di agire come molecole antagoniste per il ngf.
AT411997B (de) * 1999-09-14 2004-08-26 Baxter Ag Faktor ix/faktor ixa aktivierende antikörper und antikörper-derivate
FR2807660A1 (fr) 2000-04-13 2001-10-19 Warner Lambert Co Utilisation d'antagonistes du ngf pour la prevention ou le traitement de douleurs viscerales chroniques
NZ587701A (en) 2008-02-04 2013-03-28 Lay Line Genomics Spa Anti-trka antibodies and derivatives thereof

Also Published As

Publication number Publication date
US7601352B1 (en) 2009-10-13
CA2373274C (en) 2012-08-14
ES2218163T3 (es) 2004-11-16
US20110206682A1 (en) 2011-08-25
AU776457B2 (en) 2004-09-09
PT1181318E (pt) 2004-08-31
DK1181318T3 (da) 2004-07-12
CA2373274A1 (en) 2000-12-07
DE60009484T2 (de) 2005-03-24
AU5101900A (en) 2000-12-18
JP4917226B2 (ja) 2012-04-18
WO2000073344A9 (en) 2002-03-07
DK1181318T4 (da) 2012-05-29
DE60009484D1 (de) 2004-05-06
WO2000073344A3 (en) 2001-06-28
US8486401B2 (en) 2013-07-16
DE60009484T3 (de) 2012-06-14
ITRM990333A0 (it) 1999-05-26
WO2000073344A2 (en) 2000-12-07
ES2218163T5 (es) 2012-06-06
EP1181318B1 (en) 2004-03-31
JP2003502029A (ja) 2003-01-21
ATE263188T1 (de) 2004-04-15
EP1181318A2 (en) 2002-02-27
JP2012040007A (ja) 2012-03-01
EP1181318B2 (en) 2012-03-28
ITRM990333A1 (it) 2000-11-26

Similar Documents

Publication Publication Date Title
IT1306704B1 (it) Anticorpi monoclonali e suoi derivati sintetici o biotecnologici ingrado di agire come molecole antagoniste per il ngf.
DK1287130T3 (da) Cytokinreceptorunderenhedproteiner fra pattedyr, tilhörende reagenser og fremgangsmåder
NO20062886L (no) IL-23 og dens reseptor, beslektede reagenser og fremgangsmater
DE60025832D1 (de) Mehrere zytokin-antikörper komplexen
CY1109093T1 (el) Πρωτεϊνες των υποδοχεων θηλαστικων, σχετικα αντιδραστηρια και σχετικες μεθοδοι
BR0113921A (pt) ácidos nucléicos e polipeptìdeos receptores
ATE469913T1 (de) Antagonisten des nogo-rezeptors
WO2001090358A3 (en) Mammalian receptor proteins; related reagents and methods
EP1433792A8 (en) Human receptor proteins, related reagents and methods
PT759942E (pt) Receptor de interleucina-15
EP2292760A3 (en) Mammalian cytokines, receptors, related reagents and methods
WO1999046379A3 (en) Human receptor proteins; related reagents and methods
NZ515382A (en) OX2 receptor homologs
BR9611947A (pt) Isoindolonas fundidas como inibidores da quinase da proteina c
WO2005065711A3 (en) Mammalian receptor proteins; related reagents and methods
DE60045637D1 (de) Nicotin-acetylcholin rezeptoruntereinheit, deren isolierung und verwendung
CY1114280T1 (el) Αντισωματα ανταγωνιστων των κυτοκινων θηλαστικων ή οι υποδοχεις τους για την αγωγη της αλλεργιας